Tag: Chugai Pharmaceutical
January 4, 2017
Roche Launches cobas® c 513 analyzer and HbA1c Gen. 3 assay
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its new dedicated, high-throughput HbA1c testing solution, the cobas c 513... October 5, 2016
Chugai's ACTEMRA/RoACTEMRA Receives Breakthrough Therapy Designation from FDA
Chugai Pharmaceutical announced that the US Food and Drug Administration has granted Breakthrough Therapy Designation to ACTEMRA®/RoACTEMRA® (tocilizumab), a Chugai... October 4, 2016
Chugai's Alecensa Receives Breakthrough Therapy Designation from FDA
Chugai Pharmaceutical announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the first-line... September 30, 2016
US FDA Approves TAGRISSO® (osimertinib) Blood-Based T790M Companion Diagnostic Test
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved a blood-based companion diagnostic for TAGRISSO® (osimertinib). September 29, 2016